Pink SheetNovo Nordisk and Eli Lilly are succeeding with National Advertising Division challenges of marketing claims for compounded versions of the GLP-1 agonists semaglutide and tirzepatide. In four new NA
In VivoThe phenomenal success of glucagon-like peptide-1 (GLP-1) receptor agonists in treating diabetes and obesity has sparked a wave of clinical investigations into their potential applications far beyond
ScripRegeneron is acquiring a dual GIP/GLP-1 agonist – a similar product to Eli Lilly’s blockbuster tirzepatide – to develop proprietary combinations that could deliver similar or even better weight loss b
Pink SheetEli Lilly and Novo Nordisk may be considering big US price reductions for GLP-1 drugs for obesity and diabetes, at least partly in response to President Trump’s recent executive order on Most Fav